Four RI-MUHC trainees win laurels on a national platform
Congratulations to the many RI-MUHC trainees distinguished recently for their innovative work, and welcome to next year’s candidates!
RI-MUHC researchers introduce a scalable, cost-effective solution for single-cell profiling
An innovative computational tool, scSemiProfiler, makes powerful single-cell sequencing technology more...
Circadian rhythms appear to influence vulnerability to malaria parasites
A new discovery could lead to more effective treatment of malaria and other parasitic diseases.
Exponential growth - 2024 Summer student research event hits record-breaking numbers
A record number of presenters representing every research program contributed to a day filled with...
Eight RI-MUHC trainees earn 2024 EDI award for academic excellence
The awards for Equity, Diversity and Inclusion in health care research recognize the academic excellence...
After a tragic loss, a career devoted to organ regeneration
Darcy Wagner, PhD, leads the charge in advancing bioengineered therapies for acute and chronic lung diseases, centred on advanced 3D bioprinting...
Triple-negative breast cancer: new hope for an existing drug
RI-MUHC team takes another step toward precision medicine by targeting a biomarker of CDK4/6 inhibitor efficacy in breast cancer, including triple-negative...
Prescribing personalized lifestyle interventions to improve prostate cancer treatments
David Labbé of the RI-MUHC co-leads a new project recently funded by the Marathon of Hope Cancer Centres...
Researchers find a possible therapeutic target in the “genetic landscape” of aggressive and deadly pediatric brain tumours
A new study reveals that PFA ependymoma brain tumours display...
McGill, industry, CQDM and Brain Canada collaborate for drug discovery
Novel drug could provide hope to those suffering from neuropathic pain and insomnia